[{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Aleor Dermaceuticals \/ Alembic Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Alembic Pharmaceuticals Limited"},{"orgOrder":0,"company":"Reig Jofre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Reig Jofre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Reig Jofre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reig Jofre \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Duke University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Duke University \/ Bristol Myers Squibb"}]

Find Clinical Drug Pipeline Developments & Deals for Centany

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Duke University

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Duke University

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Details : Mupirocin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 07, 2024

                          Lead Product(s) : Mupirocin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Bristol Myers Squibb

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Mupirocin cream USP, 2% is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.

                          Product Name : Mupirocin

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 17, 2021

                          Lead Product(s) : Mupirocin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Alembic Pharmaceuticals Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Mupirocin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Impetigo.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          February 27, 2020

                          Lead Product(s) : Mupirocin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank